v3.25.2
Segment Reporting (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2025
USD ($)
segment
Jun. 30, 2024
USD ($)
Segment Reporting [Abstract]        
Number of reportable segments | segment     1  
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Product revenues, net $ 107,415 $ 90,340 $ 200,238 $ 165,840
Cost of product revenues (excluding amortization of intangible assets) 28,075 20,964 49,353 38,421
Research and development 177,190 146,748 329,767 267,831
Amortization of intangible assets 1,263 1,263 2,526 2,526
Change in fair value of deferred and contingent consideration liabilities 59,000 103,700 77,300 91,800
Investment income 13,225 10,285 27,131 19,068
Interest expense (21,245) (21,267) (42,814) (42,309)
Provision for income taxes 1,243 838 2,155 1,427
Reportable Segment        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Product revenues, net 107,415 90,340 200,238 165,840
Cost of product revenues (excluding amortization of intangible assets) 28,075 20,964 49,353 38,421
R&D compensation and benefit-related expenses 56,389 43,908 109,947 85,368
SG&A compensation and benefit-related expenses 51,320 35,087 106,156 67,672
Other segment items 127,650 90,379 247,345 167,168
Depreciation 2,484 1,436 4,367 3,024
Amortization of intangible assets 1,263 1,263 2,526 2,526
Change in fair value of deferred and contingent consideration liabilities 59,000 103,700 77,300 91,800
Investment income (13,225) (10,285) (27,131) (19,068)
Interest expense 21,245 21,267 42,814 42,309
Provision for income taxes 1,243 838 2,155 1,427
Segment net loss (321,686) (300,609) (578,269) (457,700)
Reportable Segment | ARIKAYCE external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 11,003 14,896 23,124 28,822
Reportable Segment | Brensocatib external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 33,560 37,806 54,221 57,324
Reportable Segment | TPIP external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development 20,649 14,773 29,802 28,555
Reportable Segment | Other external R&D expenses        
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]        
Research and development $ 28,445 $ 14,917 $ 56,528 $ 28,192